• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

菲律宾的狂犬病暴露后预防:接受纯化马 F(ab')(2) 片段狂犬病免疫球蛋白 (Favirab) 的患者的健康状况。

Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab).

机构信息

Research Institute for Tropical Medicine, Alabang, Manila, Philippines.

出版信息

PLoS Negl Trop Dis. 2008 May 28;2(5):e243. doi: 10.1371/journal.pntd.0000243.

DOI:10.1371/journal.pntd.0000243
PMID:18509475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2386244/
Abstract

BACKGROUND

Recommended treatment for severe rabies exposure in unvaccinated individuals includes wound cleaning, administration of rabies immunoglobulins (RIG), and rabies vaccination. We conducted a survey of rabies treatment outcomes in the Philippines.

METHODS

This was a case series involving 7,660 patients (4 months to 98 years of age) given purified equine RIG (pERIG) at the Research Institute for Tropical Medicine (Muntinlupa, Philippines) from July 2003 to August 2004 following Category II or III exposures. Data on local and systemic adverse reactions (AR) within 28 days and biting animal status were recorded; outcome data were obtained by telephone or home visit 6-29 months post-exposure.

RESULTS

Follow-up data were collected for 6,464 patients. Of 151 patients with laboratory-confirmed rabies exposure, 143 were in good health 6-48 months later, seven could not be contacted, and one 4-year-old girl died. Of 16 deaths in total, 14 were unrelated to rabies exposure or treatment. Two deaths were considered PEP failures: the 4-year old girl, who had multiple deep lacerated wounds from a rabid dog of the nape, neck, and shoulders requiring suturing on the day of exposure, and an 8-year-old boy who only received rabies PEP on the day of exposure.

CONCLUSIONS

This extensive review of outcomes in persons with Category III exposure shows the recommended treatment schedule at RITM using pERIG is well tolerated, while survival of 143 laboratory-confirmed rabies exposures confirms the intervention efficacy. Two PEP intervention failures demonstrate that sustained education and training is essential in rabies management.

摘要

背景

对于未接种疫苗的重度狂犬病暴露者,推荐的治疗方法包括伤口清洗、狂犬病免疫球蛋白(RIG)的使用以及狂犬病疫苗的接种。我们对菲律宾的狂犬病治疗结果进行了一项调查。

方法

这是一项病例系列研究,涉及 7660 名患者(4 个月至 98 岁),他们于 2003 年 7 月至 2004 年 8 月期间在菲律宾蒙廷卢帕的热带医学研究所(Research Institute for Tropical Medicine)接受了纯化马源狂犬病免疫球蛋白(pERIG)治疗,这些患者的暴露情况属于 II 类或 III 类。记录了 28 天内局部和全身不良反应(AR)以及咬伤人的动物状况的数据;通过电话或家访获得暴露后 6-29 个月的结局数据。

结果

共收集到 6464 名患者的随访数据。在 151 名经实验室证实的狂犬病暴露患者中,143 名在 6-48 个月后身体健康,7 名无法联系,1 名 4 岁女孩死亡。在总共 16 例死亡中,有 14 例与狂犬病暴露或治疗无关。两名死亡被认为是 PEP 失败:一名 4 岁女孩被患有狂犬病的狗从颈背部和肩部多处严重撕裂伤,需要在暴露当天进行缝合,另一名 8 岁男孩仅在暴露当天接受了狂犬病 PEP。

结论

对 III 类暴露者结局的广泛回顾表明,RITM 使用 pERIG 的推荐治疗方案具有良好的耐受性,而 143 例经实验室证实的狂犬病暴露者的存活证明了干预的有效性。两次 PEP 干预失败表明,在狂犬病管理中持续的教育和培训至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/763c/2386244/391ec5328035/pntd.0000243.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/763c/2386244/391ec5328035/pntd.0000243.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/763c/2386244/391ec5328035/pntd.0000243.g001.jpg

相似文献

1
Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab).菲律宾的狂犬病暴露后预防:接受纯化马 F(ab')(2) 片段狂犬病免疫球蛋白 (Favirab) 的患者的健康状况。
PLoS Negl Trop Dis. 2008 May 28;2(5):e243. doi: 10.1371/journal.pntd.0000243.
2
Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines.狂犬病暴露后预防用纯化马抗狂犬病免疫球蛋白:菲律宾实验室确诊的狂犬病 III 级暴露患者的一年随访。
Vaccine. 2009 Nov 27;27(51):7162-6. doi: 10.1016/j.vaccine.2009.09.036.
3
Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.皮内暴露后狂犬病疫苗接种用纯化 Vero 细胞狂犬病疫苗:在菲律宾一项随机非劣效性试验中,比较一周 4 部位方案与泰国红十字会更新方案。
Vaccine. 2019 Apr 10;37(16):2268-2277. doi: 10.1016/j.vaccine.2019.02.083. Epub 2019 Mar 16.
4
Post-exposure rabies prophylaxis in humans exposed to animals in Lublin province (Eastern Poland) in 2012-2015 - A retrospective study.2012 - 2015年波兰东部卢布林省动物致伤后人类狂犬病暴露后预防——一项回顾性研究
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-6. doi: 10.1080/21645515.2017.1285474. Epub 2017 Feb 6.
5
Wound-only injection of rabies immunoglobulin (RIG) saves lives and costs less than a dollar per patient by "pooling strategy".伤口局部浸润注射狂犬病免疫球蛋白(RIG)通过“集中策略”可挽救生命,每位患者的费用还不到 1 美元。
Vaccine. 2019 Oct 3;37 Suppl 1:A128-A131. doi: 10.1016/j.vaccine.2019.07.087. Epub 2019 Aug 5.
6
Local infiltration of rabies immunoglobulins without systemic intramuscular administration: An alternative cost effective approach for passive immunization against rabies.狂犬病免疫球蛋白局部浸润而非全身肌内注射:一种具有成本效益的狂犬病被动免疫替代方法。
Hum Vaccin Immunother. 2016 Mar 3;12(3):837-42. doi: 10.1080/21645515.2015.1085142.
7
Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab') fragments.二十年的高纯度狂犬病免疫球蛋白 F(ab')片段的药物警戒和临床经验。
Expert Rev Vaccines. 2017 Mar;16(3):273-287. doi: 10.1080/14760584.2017.1244009. Epub 2016 Nov 4.
8
Awareness about rabies post exposure prophylaxis in Pakistan among patients and health care workers: results from an Asian Rabies Expert Bureau study.巴基斯坦患者和医护人员对狂犬病暴露后预防的认知:亚洲狂犬病专家局研究结果
J Coll Physicians Surg Pak. 2011 Aug;21(8):491-4.
9
A multicentric community survey on animal exposures among humans in India.印度人群中动物暴露的多中心社区调查。
Indian J Public Health. 2019 Sep;63(Supplement):S9-S14. doi: 10.4103/ijph.IJPH_374_19.
10
Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines.一种新型经色谱纯化的Vero细胞狂犬病疫苗(CPRV)用于暴露后狂犬病预防的免疫原性和有效性:菲律宾的一项两阶段随机临床试验
Acta Trop. 2000 Feb 25;75(1):39-52. doi: 10.1016/s0001-706x(99)00092-3.

引用本文的文献

1
INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome.INM004:抗志贺毒素多克隆中和抗体作为溶血尿毒综合征的一种治疗方法。
Toxins (Basel). 2025 Jun 5;17(6):282. doi: 10.3390/toxins17060282.
2
Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab') fragments.针对 SARS-CoV-2 的羊源免疫球蛋白治疗的改良,比较全 IgG 与 F(ab')片段。
Sci Rep. 2023 Aug 25;13(1):13912. doi: 10.1038/s41598-023-40277-4.
3
Effect of Phone Text Message Reminders on Compliance with Rabies Post-Exposure Prophylaxis following Dog Bites in Rural Kenya.

本文引用的文献

1
Is injecting a finger with rabies immunoglobulin dangerous?给手指注射狂犬病免疫球蛋白危险吗?
Am J Trop Med Hyg. 2006 Aug;75(2):363-4.
2
Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey.评估印度人间狂犬病负担:一项全国多中心流行病学调查结果
Int J Infect Dis. 2007 Jan;11(1):29-35. doi: 10.1016/j.ijid.2005.10.007. Epub 2006 May 4.
3
WHO Expert Consultation on rabies.世界卫生组织狂犬病专家磋商会
手机短信提醒对肯尼亚农村地区犬咬伤后狂犬病暴露后预防措施依从性的影响。
Vaccines (Basel). 2023 Jun 18;11(6):1112. doi: 10.3390/vaccines11061112.
4
Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.具有高效广谱中和活性的治疗性马源高免抗体可保护啮齿动物免受 SARS-CoV-2 感染。
Front Immunol. 2023 Feb 17;14:1066730. doi: 10.3389/fimmu.2023.1066730. eCollection 2023.
5
Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review.在临床研究受试者和患者中使用七价肉毒杆菌毒素抗毒素(A、B、C、D、E、F、G)(BAT):15 年系统安全性综述。
Toxins (Basel). 2021 Dec 27;14(1):19. doi: 10.3390/toxins14010019.
6
Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.CoviFab,一种源自马多克隆抗体的 RBD 特异性 F(ab')2 片段,其非临床安全性评估和体内生物分布。
Toxicol Appl Pharmacol. 2022 Jan 1;434:115796. doi: 10.1016/j.taap.2021.115796. Epub 2021 Nov 14.
7
A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.一种基于单次剂量的 chimpanzee 腺病毒载体血清型 C 的新一代人狂犬病疫苗。
PLoS Negl Trop Dis. 2020 Jul 15;14(7):e0008459. doi: 10.1371/journal.pntd.0008459. eCollection 2020 Jul.
8
mRNA: A Novel Avenue to Antibody Therapy?mRNA:抗体治疗的新途径?
Mol Ther. 2019 Apr 10;27(4):773-784. doi: 10.1016/j.ymthe.2019.03.002. Epub 2019 Mar 6.
9
Scoping decades of dog evidence: a scoping review of dog bite-related sequelae.探究数十年的犬类证据:犬咬伤相关后遗症的范围综述。
Can J Public Health. 2019 Jun;110(3):364-375. doi: 10.17269/s41997-018-0145-3. Epub 2018 Oct 30.
10
Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.联合工作组报告,涉及美国过敏、哮喘和免疫学会(AAAAI);食物过敏、过敏反应、皮肤病和药物过敏(FADDA)(食物不良反应委员会和药物、生物制品和乳胶不良反应委员会);以及疾病控制和预防中心肉毒杆菌临床治疗指南工作组-肉毒杆菌抗毒素过敏反应:系统评价。
Clin Infect Dis. 2017 Dec 27;66(suppl_1):S65-S72. doi: 10.1093/cid/cix827.
World Health Organ Tech Rep Ser. 2005;931:1-88, back cover.
4
Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animals.暴露于疑似患有狂犬病动物的营养不良儿童的狂犬病暴露后预防措施。
Vaccine. 2005 Jan 19;23(9):1102-5. doi: 10.1016/j.vaccine.2004.08.036.
5
A tale of two worlds: public health management decisions in human rabies prevention.两个世界的故事:人类狂犬病预防中的公共卫生管理决策
Clin Infect Dis. 2004 Jul 15;39(2):281-3. doi: 10.1086/421563. Epub 2004 Jun 18.
6
Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model.狂犬病免疫球蛋白在实验性暴露后预防啮齿动物模型中的疗效。
Vaccine. 2003 Dec 12;22(2):244-9. doi: 10.1016/s0264-410x(03)00559-0.
7
The incurable wound revisited: progress in human rabies prevention?再探无法治愈的伤口:人类狂犬病预防取得进展了吗?
Vaccine. 2001 Mar 21;19(17-19):2273-9. doi: 10.1016/s0264-410x(00)00516-8.
8
A study of human rabies immune globulin manufactured by the Thai Red Cross.泰国红十字会生产的人狂犬病免疫球蛋白研究。
Vaccine. 1999 Feb 26;17(7-8):979-81. doi: 10.1016/s0264-410x(98)00314-4.
9
Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine.对一种新的、高度纯化的、热处理马狂犬病免疫球蛋白单独使用或与纯化的Vero细胞狂犬病疫苗联合使用时的安全性、免疫原性和药代动力学特征进行评估。
Acta Trop. 1998 Jul 30;70(3):317-33. doi: 10.1016/s0001-706x(98)00038-2.